Oncogene. 2009 Mar 19;28(11):1465-70. Epub 2009 Feb 2.

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.

McCabe N, Cerone MA, Ohishi T, Seimiya H, Lord CJ, Ashworth A.

Source

Cancer Research UK Gene Function and Regulation Group, Institute of Cancer Research, London, UK.

Abstract

The BRCA1 and BRCA2 proteins are involved in the maintenance of genome stability and germ-line loss-of-function mutations in either BRCA1 or BRCA2 strongly predispose carriers to cancers of the breast and other organs. It has been demonstrated previously that inhibiting elements of the cellular DNA maintenance pathways represents a novel therapeutic approach to treating tumors in these individuals. Here, we show that inhibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA deficiency. We also demonstrate that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the centrosome amplification phenotype associated with BRCA deficiency. We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCA-associated cancers.

PMID:: 19182824; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Related citations

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. [Cold Spring Harb Symp Quant Biol. 2005]
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.
Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Cold Spring Harb Symp Quant Biol. 2005; 70:139-48.
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. [Breast Cancer Res Treat. 2003]
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E, Tancredi M, Aretini P, Cipollini G, Naccarato AG, Viacava P, Bevilacqua G, Caligo MA. Breast Cancer Res Treat. 2003 Nov; 82(1):1-9.
Review Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. [Cancer Sci. 2004]
Review Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
Yoshida K, Miki Y. Cancer Sci. 2004 Nov; 95(11):866-71.
Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country. [World J Surg. 2009]
Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH. World J Surg. 2009 Oct; 33(10):2077-81.
Review [BRCA 1 and BRCA 2 gens in breast cancer]. [Lijec Vjesn. 1998]
Review [BRCA 1 and BRCA 2 gens in breast cancer].
Habibović S, Hrgović Z. Lijec Vjesn. 1998 Oct-Nov; 120(10-11):342-8.

See reviews... See all...

Cited by 6 PubMed Central articles

Review Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. [J Hematol Oncol. 2011]
Review Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. J Hematol Oncol. 2011 Apr 20; 4:16. Epub 2011 Apr 20.
Review PARP inhibitor treatment in ovarian and breast cancer. [Curr Probl Cancer. 2011]
Review PARP inhibitor treatment in ovarian and breast cancer.
Weil MK, Chen AP. Curr Probl Cancer. 2011 Jan-Feb; 35(1):7-50.
The telomere protein tankyrase 1 regulates DNA damage responses at telomeres. [Aging (Albany NY). 2010]
The telomere protein tankyrase 1 regulates DNA damage responses at telomeres.
Chang S. Aging (Albany NY). 2010 Oct; 2(10):639-42.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
Oncogene. 2009 Mar 19 ;28(11):1465-70. Epub 2009 Feb 2 .

PubMed
The West Midlands "Severe Hypertensive Illness in Pregnancy" (SHIP) audit.
The West Midlands "Severe Hypertensive Illness in Pregnancy" (SHIP) audit.
Hypertens Pregnancy. 2001 ;20(3):257-68.

PubMed
Increased frequency of pre-germinal center B cells and plasma cell precursors in...
Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus.
J Immunol. 2001 Aug 15 ;167(4):2361-9.

PubMed
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourie...
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform.
Nucleic Acids Res. 2002 Jul 15 ;30(14):3059-66.

PubMed
Amino acid supplementation and voluntary alcohol consumption by rats.
Amino acid supplementation and voluntary alcohol consumption by rats.
J Biol Chem. 1956 May ;220(1):321-3.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: